

FIRST NAME	MI	LAST NAME
EMAIL ADDRESS	TELEPHONE	FAX
INSTITUTE	DEPARTMENT	
ADDRESS		
CITY	STATE/PROVINCE	ZIP/POSTAL CODE
COUNTRY		
PAYMENT METHOD		
<input type="radio"/> American Express <input type="radio"/> MasterCard <input type="radio"/> Visa		
<input type="radio"/> Check in the amount of \$		
CARDHOLDERS NAME	SIGNATURE	
CARD NUMBER	EXP. DATE	

To pre-register, registration and payment must be received no later than March 5, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242-0906 or visit our website at www.imedex.com to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full.


For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than March 5, 2009. The amount of registration fees refunded, minus a \$50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after March 5, 2009.


Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda content is subject to change without notice.

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda's content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, Imedex EXPRESSLY DISCLAIMS ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Imedex does not make any representation or warranty, IN ANY MANNER, ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual's own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society. © 2009 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

3 WAYS TO LEARN:

 PRINT materials are produced by Imedex for your reference needs

 ONLINE products are produced by Imedex in 6 user-friendly formats

 LIVE meetings are produced by Imedex in 15 countries

Visit www.imedex.com to learn more.



Imedex® is committed to environmental excellence. This publication is printed on paper which is acid-free and elemental chlorine-free and contains 50% recycled content including 25% post-consumer waste.

4325 Alexander Dr.
Alpharetta, GA 30022-3740

15th ANNUAL NOCR MEETING

March 13-14, 2009
Las Vegas, Nevada, USA
Westin Casuarina Las Vegas Hotel



15th ANNUAL NOCR MEETING

Organized for **NOCR**
The Oncology Professional's Network



The premier annual event for
community oncologists to update
their clinical knowledge

March 13-14, 2009
Las Vegas, Nevada, USA
Westin Casuarina Las Vegas Hotel
Second Announcement

EDUCATION IS THE BEST MEDICINE®

WWW.IMEDEX.COM





15th ANNUAL NOCR MEETING

March 13-14, 2009
Las Vegas, Nevada, USA

Faculty

Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

David H. Ilson, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Tracy T. Batchelor, MD, MPH
Massachusetts General Hospital
Boston, Massachusetts

John Kirkwood, MD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Jorge Cortes, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Corey Langer, MD, FACP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Christopher Crane, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ruth O'Regan, MD
Emory University
Atlanta, Georgia

Myron Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

Robert Z. Orlowski, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

James Epstein, MD
Imedex, LLC
Alpharetta, Georgia

Shreyaskumar Patel, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Mark Pegram, MD
University of Miami
Miami, Florida

Edward P. Gelmann, MD
Herbert Irving Comprehensive Cancer Center
Columbia University
Milstein
New York, New York

Christy Russell, MD
University of Southern California
Los Angeles, California

Ramaswamy Govindan, MD
Washington University School of Medicine
St. Louis, Missouri

Mark A. Socinski, MD
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Axel Grothey, MD
Mayo Clinic College of Medicine
Rochester, Minnesota

Deborah Toppmeyer, MD
The Cancer Institute of New Jersey
New Brunswick, New Jersey

Tom Herzog, MD
Columbia University Medical Center
New York, New York

Alan Venook, MD
USCF Medical Center
San Francisco, California

Tim Hobday, MD
Mayo Clinic Medical School
Rochester, Minnesota

Nicholas J. Volgelzang, MD
Nevada Cancer Institute
Las Vegas, Nevada

Continuing Medical Education



Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 12.5 of *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for oncologists, hematologists and other healthcare professionals interested and/or involved in the care of patients with cancer.

Objectives

After successful completion of this activity, participants should be able to:

- Discuss recent clinical advances among a wide range of cancer disciplines as they relate to the therapeutic management of the disease
- Describe and evaluate areas of clinical controversy in the management of various malignancies
- Recommend treatment modalities and emerging therapeutic approaches based upon the assimilation of expert-guided case presentations
- Discuss the clinical significance of targeted therapy in terms of complete response, prolonged survival and quality of life issues
- Highlight therapeutic advances and clinical updates in orphan cancers such as sarcomas, melanomas, head and neck cancer, neuro-oncology and gynecological malignancies

Conference Organizer



4325 Alexander Drive
Alpharetta, Georgia
30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com



March 13-14, 2009
Las Vegas, Nevada, USA
 Westin Casuarina Las Vegas Hotel

Corporate Support

The following companies have provided educational grants in support of this conference:

Platinum:

Genentech BioOncology

Silver:



Bronze:



Millennium Pharmaceuticals, Inc.

Corporate:



Oncology

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Scientific Agenda

Friday, March 13, 2009

7:00 am Breakfast

8:00 am Welcome and introduction

Session I: Keynote Address

Moderator: James Epstein, MD

8:10 am The importance of Ras mutations and their clinical significance in oncology

Alan Venook, MD

8:50 am Q & A

Session II: Gastrointestinal Cancers

Moderator: Axel Grothey, MD

9:00 am Personalized medicine for GI cancers: Are we there yet?

Axel Grothey, MD

9:25 am Combining EGFR and VEGF/VEGFR targeted therapies: Advantage or Adversity?

Alan Venook, MD

9:50 am Debate: The role of combined modality therapy in locally advanced pancreatic cancer

Christopher Crane, MD vs. David H. Ison, MD

10:15 am Coffee break

10:35 am Therapeutic advances in gastrointestinal neuroendocrine tumors

Tim Hobday, MD

11:00 am Case presentation & discussion

Case 1: Advanced CRC relapsed post FOL-FOX-bevacizumab

Case 2: Locally advanced adenocarcinoma of the GE junction

Moderator: Axel Grothey, MD

Panel: Christopher Crane, MD, Tim Hobday, MD and David H. Ison, MD

Session III: Breast Cancer

Moderator: Christy Russell, MD

11:25 am Management of bone related issues in breast cancer - Which therapy for which patient?

Christy Russell, MD

11:50 am Triple negative breast cancer: Advances in the epidemiology, genomics and management

Ruth O'Regan, MD

12:15 pm Lunch

1:15 pm Controversies & challenges in HER2 over-expressed breast cancer

Mark Pegram, MD

1:40 pm Case presentation & discussion

Case 1: Pre-menopausal woman with ER/PR+ node-negative breast cancer

Case 2: Relapsed metastatic HER2+ breast cancer

Moderator: Christy Russell, MD

Panel: Ruth O'Regan, MD, Mark Pegram, MD and Deborah Toppmeyer, MD

Session IV: Meet the Experts

2 Concurrent Sessions

2:05 pm Advances in the management of ER/PR+ breast cancer

Deborah Toppmeyer, MD

Evaluating and managing the older patient with acute leukemia

Jorge Cortes, MD

2:50 pm Coffee break

Session V: Hematologic Oncology

Moderator: Robert Z. Orlowski, MD, PhD

3:10 pm Advances in myeloproliferative disorders

Jorge Cortes, MD

3:35 pm Emerging therapies for lymphoproliferative disorders

Myron Czuczman, MD

4:00 pm Evidence based management algorithm for newly diagnosed transplant eligible multiple myeloma patients

Robert Z. Orlowski, MD, PhD

4:25 pm Meeting summary & adjourn

5:00 pm Evening reception

Saturday, March 14, 2009

7:00 am Breakfast

Session VI: Early Bird - Meet the Experts

2 Concurrent Sessions

7:10 am Stage III NSCLC: Putting clarity into heterogeneity

Mark A. Socinski, MD

Management strategies for the high risk myeloma patient

Rafael Fonseca, MD

8:00 am Introductions

Session VII: Lung Cancer

Moderator: James Epstein, MD

8:10 am Debate: Should patients undergo tumor testing for EGFR copy number, EGFR mutation status or Kras mutation status before receiving EGFR targeted therapy?

Corey Langer, MD, FACP vs. Mark A. Socinski, MD

8:35 am Small cell lung cancer: Is there any good news?

Ramaswamy Govindan, MD

9:00 am Novel agents in NSCLC

Ramaswamy Govindan, MD

9:25 am Case presentation & discussion

Case 1: Newly diagnosed advanced adenocarcinoma in a non-smoking female

Moderator: James Epstein, MD

Panel: Ramaswamy Govindan, MD, Corey Langer, MD, FACP and Mark A. Socinski, MD

9:50 am Coffee break

Session VIII: Mini-Symposium: Advances in Orphan Cancers

Moderator: Christy Russell, MD

10:10 am Emerging therapies for GYN malignancies

Tom Herzog, MD

10:35 am Clinical update in management of soft tissue sarcomas

Shreyaskumar Patel, MD

11:00 am Advances in the management of malignant melanoma

John Kirkwood, MD

11:25 am Head & neck cancers: Recent advances in management

Corey Langer, MD, FACP

12:00 pm Clinical update on neuro-oncology

Tracy T. Batchelor, MD, MPH

12:25 pm Lunch

Session IX: Genitourinary Cancer

Moderator: Dean F. Bajorin, MD

2:00 pm Emerging novel therapies for hormone refractory prostate cancer

Edward P. Gelmann, MD

2:25 pm Triumphs and cautions in the management of advanced renal cell carcinoma

Nicholas J. Volgelzang, MD

3:00 pm Case presentation & discussion

Case 1: Newly diagnosed high risk advanced RCC

Case 2: Relapsed metastatic RCC post-sunitinib therapy

Case 3: T3 TCC of bladder: neoadjuvant therapy or resection plus adjuvant therapy

Moderator: Edward Gelmann, MD and Nicholas J. Volgelzang, MD

3:25 pm Meeting summary & adjourn



Registration Fees

Physicians	\$125.00
Nurses, Students and Fellows <i>Proof of eligibility must accompany registration</i>	\$75.00

Hotel Accommodations

The Westin Casuarina
 160 E. Flamingo Road
 Las Vegas, Nevada 89109
 Tel.: +1 (702) 836 5900 Fax: +1 (702) 836 9776
www.westin.com/lasvegas

Stay at The Westin Casuarina Las Vegas Hotel for a calm sanctuary amidst the bustle of Las Vegas. You'll enjoy the action and excitement of the famous "Strip" just one block away—and a quiet retreat whenever you need some peace. In a city known for glitz and glamour, the 826 guest rooms and suites offer understated style and the utmost elegance. Muted tones, soft lighting, and simple contemporary decor create an environment where you can't help but feel at ease.

For the convenience of attendees, a limited number of rooms have been reserved until Friday, February 20, 2009 at a discounted rate of \$159.00 single or double occupancy, plus state and local taxes, currently at 9% and the resort service fee of \$10.00 per room per day plus tax. This rate is not guaranteed outside the conference dates or after Friday, February 20, 2009.

To reserve your room please contact the Westin Casuarina reservations department at +1 (702) 836 5900 or visit the hotel's website at <http://www.starwoodmeeting.com/StarGroupsWeb/res?id=0810249018&key=E2428>. To receive the group rate, callers must identify themselves as being with the NOCR Annual Meeting group. Reservation requests received after Friday, February 20, 2009 may not be guaranteed the group rate.

All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card. The Hotel will not hold any reservation unless secured by one of the above methods.

Cancellations received within forty-eight (48) hours prior to arrival will be charged a cancellation fee equal to one (1) night's room revenue and tax.

In the event a guest checks out before the reserved check-out date, an early departure fee of \$75.00 will be charge. Guests wishing to avoid this fee must advise the Hotel at or before check-in of any change in the scheduled length of stay.

Registration Procedures

To Register: You may register online by March 5, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

Payment: To pre-register, registration and payment must be received no later than March 5, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the announcement.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than March 5, 2009. The amount of registration fees remitted, minus a \$50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after March 5, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Four EASY ways to register



ONLINE:
www.imedex.com



FAX US:
+1 (678) 242 0920



CALL US:
+1 (678) 242 0906



MAIL US:
Imedex
4325 Alexander Drive
Alpharetta, GA
30022-3740, USA
Keep a copy for your records.

* Please visit www.imedex.com for the most up-to-date agenda and to register.